StockData
BBOTNasdaqPharmaceutical PreparationsFiscal year ends December 31

BridgeBio Oncology Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$2.85+0.03 (+1.06%)

Close on Oct 19, 2026

Market cap
$228.15M
P/E (TTM)
–
Dividend yield
–

SEC filings

30 of BridgeBio Oncology Therapeutics's most recent filings on SEC EDGAR

DocumentFormPeriodFiledSource
Current report8-KSep 8, 2026Sep 8, 2026SEC EDGAR
Quarterly report10-QJun 30, 2026Aug 11, 2026SEC EDGAR
Current report8-KAug 11, 2026Aug 11, 2026SEC EDGAR
Current report8-KJun 16, 2026Jun 22, 2026SEC EDGAR
Quarterly report10-QMar 31, 2026May 12, 2026SEC EDGAR
Current report8-KMay 12, 2026May 12, 2026SEC EDGAR
Current report8-KApr 27, 2026Apr 29, 2026SEC EDGAR
Proxy statementDEF 14AJun 16, 2026Apr 28, 2026SEC EDGAR
Current report8-KApr 20, 2026Apr 23, 2026SEC EDGAR
Current report8-KMar 24, 2026Mar 26, 2026SEC EDGAR
Annual report10-KDec 31, 2025Mar 5, 2026SEC EDGAR
Current report8-KMar 5, 2026Mar 5, 2026SEC EDGAR
Current report8-KJan 7, 2026Jan 7, 2026SEC EDGAR
Quarterly report10-QSep 30, 2025Nov 12, 2025SEC EDGAR
Current report8-KNov 12, 2025Nov 12, 2025SEC EDGAR
Current report8-KAug 11, 2025Aug 13, 2025SEC EDGAR
Current report8-KAug 6, 2025Aug 6, 2025SEC EDGAR
Current report8-KAug 4, 2025Aug 4, 2025SEC EDGAR
Quarterly report10-QJun 30, 2025Aug 1, 2025SEC EDGAR
Current report8-KJul 11, 2025Jul 11, 2025SEC EDGAR
Quarterly report10-QMar 31, 2025May 15, 2025SEC EDGAR
Annual report10-KDec 31, 2024Mar 11, 2025SEC EDGAR
Current report8-KFeb 28, 2025Mar 3, 2025SEC EDGAR
Current report8-KFeb 28, 2025Feb 28, 2025SEC EDGAR
Current report8-KFeb 8, 2025Feb 10, 2025SEC EDGAR
Quarterly report10-QSep 30, 2024Nov 14, 2024SEC EDGAR
Quarterly report10-QJun 30, 2024Aug 14, 2024SEC EDGAR
Quarterly report10-QMar 31, 2024May 15, 2024SEC EDGAR
Current report8-KFeb 13, 2024Feb 20, 2024SEC EDGAR
Current report8-KFeb 8, 2024Feb 14, 2024SEC EDGAR